BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » The Market for Induced Pluripotent Stem Cell (iPSC) Research Products – Rate of Entrants, by Year

The Market for Induced Pluripotent Stem Cell (iPSC) Research Products – Rate of Entrants, by Year

June 24, 2015 By Cade Hildreth (CEO) Leave a Comment

Are you an executive at a stem cell company that offers induced pluripotent stem cell (iPSC) research products? Or, are you an investor in a company of this type? If so, have you wondered how much market competition exists for your products or services? Have you been curious as to the rate at which this competition is increasing?  By focusing on these key points of understanding, you’ll be able to assess the technical attributes that matter, including what opportunities exist for expanding your product line and your customer reach.

Discover class-defining bioproduction tools.

iPSC research products have existed since 2006, the year in which Shinya Yamanaka’s team at Kyoto University first produced iPSCs from mouse cells.  The discovery was a vital advancement in stem cell research, as it allows researchers to obtain pluripotent stem cells without the difficult legal, technical and ethical controversies that have long surrounded deriving cells from embryos.  Yamanaka and his team reprogrammed adult mouse fibroblasts into iPSCs by introducing four reprogramming factors: Oct4, Sox2, c-Myc and Klf4.  Subsequent work by James Thomson and colleagues replicated Yamanaka’s success with human cells and revealed additional factors, Nanog and Lin28, which facilitate the reprogramming process.

Rate of Entrants into the iPSC Research Products Marketplace

By the end of 2006, the year that iPSCs were discovered, there were only two companies selling iPSC products. This number increased to seven by 2007 and then began increasing more substantially. 

Therefore, a year-over-year breakdown is shown below to indicate the rate of new entrants into the iPSC research products marketplace and current levels of market competition.  For this analysis, a manual search for iPSC product companies has been conducted every year since 2006.  

Rooster DevServices

To see a complete list of the companies selling iPSC research products, view our post “Must-Know Competitors within the iPSC Research Products Marketplace.”

Number of Companies Offering iPSC Research Products, by Year

bitbio
Year # of Companies Percent Change Over Previous Year
2006 2 N/A
2007 7 250%
2008 13 86%
2009 22 69%
2010 24 9%
2011 26 8%
2012 28 8%
2013 31  11%
2014 40 29%
2015 40 0%

Number of companies offering iPSC research products, by year

To learn more about opportunities for commercializing iPSC research products, click here to view the “Compete 2015-16 Induced Pluripotent Stem Cell (iPSC) Industry Report.”

Pluristyx

To receive future posts about the stem cell industry, sign-up here. We will never share your information with anyone, and you can opt-out at any time. No spam ever, just great stuff.

 

iPSC-derived cardiomyocte therapy

About Us

BioInformant is the only research firm that has served the stem cell sector since it emerged. Our management team comes from a BioInformatics background – the science of collecting and analyzing complex genetic codes – and applies these techniques to the field of market research. BioInformant has been featured on news outlets including the Wall Street Journal, Nature Biotechnology, CBS News, Medical Ethics, and the Center for BioNetworking.

BioInformant_Logo_header_white

Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, Beckton Dickinson, and Thermo Fisher Scientific, BioInformant is your global leader in stem cell industry data.

Rate this post

Filed Under: iPS Cells, Stem Cells Tagged With: induced pluripotent stem cells, iPSC, iPSC market, iPSC research companies, iPSC research products, market research

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Kimera Society

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram

Cart

Featured Posts

what are exosomes | definition

What are Exosomes, Exactly?

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

iPSC derived cell therapeutics

The Pipeline for iPSC-Derived Cell Therapeutics in 2022

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.